Saturday 17 October 2026 Export PMVP’s income statement to Excel — free account

PMV Pharmaceuticals, Inc.

In the quarter to June 2026, EPS grew 17.1% and free cash flow grew 20.3%, each against the same quarter a year earlier.

1.21 0.08 −6.20%

Follow PMVP

Alert me

Market cap: $97.4M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 97.42

Revenue —

Net Income (75.22)

Free Cash Flow (71.26)

Net Debt (79.43)

Current Ratio 7.70

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.90

Past 5Y EPS Growth —

This Y EPS Growth 19.26%

Next Y EPS Growth 25.10%

Next Y revenue growth —

Next 5Y EPS Growth 21.53%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 50.56%

10-year low 10-year high

EV/FCF against its own 10 years 8.30%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	204	169	113	79
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	207	176	115	81

	2023	2024	2025	Q'26
Payables	3	7	3	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	14	14	11	11

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(21.85%)	(24.78%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(20)	(15)	—	—	—
’25	(18)	(18)	(20)	(17)	(74)
’24	(16)	(2)	(17)	(17)	(51)
’23	(15)	(13)	(16)	(12)	(56)
’22	(18)	(14)	(17)	(15)	(64)
’21	(13)	(9)	(12)	(12)	(47)
’20	(8)	(7)	(7)	(10)	(33)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(20)	(15)	—	—	—
’25	(18)	(18)	(20)	(17)	(74)
’24	(17)	(2)	(17)	(16)	(52)
’23	(15)	(13)	(16)	(12)	(57)
’22	(19)	(17)	(19)	(17)	(72)
’21	(13)	(10)	(13)	(12)	(48)
’20	(8)	(7)	(7)	(10)	(33)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.34)	(0.34)	—	—	—
’25	(0.34)	(0.41)	(0.40)	(0.34)	(1.48)
’24	(0.30)	(0.02)	(0.37)	(0.45)	(1.14)
’23	(0.42)	(0.38)	(0.34)	(0.31)	(1.44)
’22	(0.41)	(0.38)	(0.40)	(0.43)	(1.61)
’21	(0.26)	(0.29)	(0.33)	(0.41)	(1.28)
’20	(2.38)	(2.62)	(1.46)	(0.73)	(2.40)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	31.05	19.73	8.13	1.18	1.40	0.81	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	62.41	63.22	24.27	9.72	3.47	1.84
People
People	Employees	—	—	—	38	44	54	62	63	47	54
	Revenue/emp, $m	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	(18)	(25)	(34)	(58)	(73)	(69)	(75)	(80)
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	(18)	(25)	(34)	(58)	(73)	(69)	(59)	(78)
	Depreciation	—	—	1	0	0	1	0	(4)	(4)	(3)
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	(5.82)	(8.35)	(2.40)	(1.28)	(1.61)	(1.44)	(1.14)	(1.48)
	Cash flow	—	—	(5.04)	(7.27)	(2.28)	(1.03)	(1.40)	(1.16)	(0.99)	(1.40)
	Capex	—	—	(0.15)	(0.04)	(0.01)	(0.03)	(0.18)	(0.02)	(0.01)	0.00
	Free cash flow	—	—	(5.19)	(7.31)	(2.29)	(1.06)	(1.57)	(1.18)	(1.00)	(1.40)
	Book value	—	—	0.00	(23.22)	25.00	6.84	5.40	4.70	3.41	1.99
	Shares, m	—	—	3	3	14	45	46	48	52	53
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(15)	(22)	(33)	(47)	(64)	(56)	(51)	(74)
	Capex	—	—	0	0	0	(1)	(8)	(1)	0	0
	Free cash flow	—	—	(16)	(22)	(33)	(48)	(72)	(57)	(52)	(74)
Balance, $m
Balance, $m	Working capital	—	—	60	98	358	289	236	193	161	104
	Total debt	—	—	107	169	—	11	14	—	—	—
	Net debt	—	—	(62)	(101)	(361)	(298)	(242)	(204)	(169)	(113)
	Shareholders’ equity	—	—	—	(70)	359	309	246	226	176	105
Returns, %
Returns, %	ROA	—	—	0.00	(49.21)	(14.70)	(16.60)	(24.36)	(26.40)	(26.48)	(50.51)
	ROIC	—	—	0.00	0.00	0.00	(344.55)	(1,159.68)	(229.63)	(805.99)	0.00
	ROE	—	—	30.08	43.48	(23.86)	(17.33)	(26.44)	(29.24)	(29.23)	(55.37)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PYPD PolyPid Ltd.	$99.5M	— (loss-making)	—	—	n/m	−64.96% (below 0%: shrinking)	0.00%	0.00%	Compare
MIST Milestone Pharmaceuticals Inc.	$98.9M	— (loss-making)	— (loss-making)	−62.73% (below 0%: shrinking)	n/m	−80.81% (below 0%: shrinking)	94.28%	(4,584.97%)	Compare
CBUS Cibus, Inc.	$98.6M	— (loss-making)	— (loss-making)	+6.54% (above 0%: growing)	n/m	+31.62% (above 0%: growing)	100.00%	(1,300.30%)	Compare
PMVP PMV Pharmaceuticals, Inc.	$97.4M	— (loss-making)	—	—	n/m	+20.27% (above 0%: growing)	0.00%	0.00%
NRXS Neuraxis, Inc.	$97.2M	— (loss-making)	— (loss-making)	+115.71% (above 0%: growing)	n/m	+29.76% (above 0%: growing)	85.87%	(110.16%)	Compare
IMUX Immunic, Inc.	$96.9M	— (loss-making)	—	—	n/m	−26.79% (below 0%: shrinking)	0.00%	0.00%	Compare
ATRA Atara Biotherapeutics, Inc.	$96.9M	— (loss-making)	— (loss-making)	−96.42% (below 0%: shrinking)	n/m	+52.10% (above 0%: growing)	69.68%	(749.21%)	Compare
ANIX ANIXA BIOSCIENCES INC	$96.7M	— (loss-making)	— (loss-making)	0.00%	n/m	−17.14% (below 0%: shrinking)	0.00%	0.00%	Compare
ICCC ImmuCell Corporation	$95.9M	126×	— (loss-making)	+11.50% (above 0%: growing)	+233.33% (above 0%: growing)	+54.86% (above 0%: growing)	33.92%	26.93%	Compare
Median of peers	$97.0M	—	—	+3.27%	—	+6.31%	51.80%	(55.08%)

All 614 Biotechnology stocks →

PMV Pharmaceuticals, Inc. (PMVP) key facts

PMV Pharmaceuticals, Inc. (PMVP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PMVP traded at $1.21, a market capitalization of $97.4 million.
Return on equity was −55.4% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.